中国专家ASCO年会发言数量再创新高，港股通创新药ETF工银(159217)近一个月资金净流入额居同标的首位

Group 1 - The core viewpoint of the news highlights the strong performance of the Hong Kong Stock Connect Innovative Drug ETF, which has achieved a 68.7% increase over the past year, ranking first among similar indices [1][3] - The ETF has seen significant trading activity, with a recent trading volume of 572 million yuan and a turnover rate of 14.22%, indicating high liquidity [1] - The upcoming 2025 American Society of Clinical Oncology (ASCO) annual meeting is expected to showcase significant advancements in cancer treatment, with a focus on innovative therapies [1][2] Group 2 - Chinese innovative drug companies are gaining international recognition, with a record number of 71 original research results presented at the ASCO meeting, indicating a growing global presence [2] - The ASCO meeting is anticipated to further update clinical data and reports, potentially increasing interest in innovative drugs [2] - The positive cycle of innovation, commercialization, and reinvestment in research is being validated, with expectations that "License out + equity cooperation" will become mainstream for international expansion [2] Group 3 - The National Index for Hong Kong Stock Connect Innovative Drugs has a low price-to-earnings ratio of 27.25, indicating a favorable valuation position [3] - The index's constituent stocks are heavily concentrated in the biopharmaceutical and chemical drug sectors, which together account for 94.2% of the index [3] - The ETF has the lowest fee rate among similar products, which reduces holding costs and enhances liquidity through T+0 trading [3]